Abstract
Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have